Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

Increased prevalence of the BRCA2 polymorphic stop codon K3326X among individuals with familial pancreatic cancer

Abstract

Germline BRCA2 mutations predispose to the development of pancreatic cancer. A polymorphic stop codon in the coding region of BRCA2 (K3326X) has been described, and although an initial epidemiological study suggested it was not disease causing, subsequent studies have been inconclusive. To investigate the biological significance of the K3326X polymorphism, we determined its prevalence in patients with sporadic and familial pancreatic cancer. Using a case–control design, we studied 250 patients with resected sporadic pancreatic adenocarcinomas, 144 patients with familial pancreatic adenocarcinoma, 115 spouses of patients with pancreatic cancer, and a disease control group of 135 patients without a personal history of cancer who had undergone cholecystectomy for non-neoplastic disease. The K3326X polymorphism was detected using heteroduplex analysis and DNA sequencing. The BRCA2 K3326X polymorphism was significantly more prevalent in individuals with familial pancreatic cancer: 8/144 (5.6%) vs 3/250 controls (1.2%) (odds ratio, 4.84; 95% CI, 1.27–18.55, P<0.01). One K3326X carrier with familial pancreatic cancer carried an alteration (IVS 16-2A>G) suspected to be deleterious. Excluding this case did not alter the significance of the association (OR: 4.24, P<0.01). In contrast, there was no difference in prevalence among individuals with sporadic pancreatic cancer – 7/250 (OR: 2.37, 95% CI: 0.61–9.27). The increased prevalence of the BRCA2 K3326X polymorphism in patients with familial pancreatic cancer suggests that this polymorphism is deleterious and contributes to pancreatic cancer risk.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  • The Breast Cancer Linkage Consortium. (1999). J. Natl. Cancer Inst., 91, 1310–1316.

  • Bartsch DK, Sina-Frey M, Lang S, Wild A, Gerdes B, Barth P, Kress R, Grutzmann R, Colombo-Benkmann M, Ziegler A, Hahn SA, Rothmund M and Rieder H . (2002). Ann. Surg., 236, 730–737.

  • Claes K, Poppe B, Machackova E, Coene I, Foretova L, De Paepe A and Messiaen L . (2003). Genes Chromosomes Cancer, 37, 314–320.

  • DiMagno EP, Reber HA and Tempero MA . (1999). Gastroenterology, 117, 1464–1484.

  • Figer A, Irmin L, Geva R, Flex D, Sulkes J, Sulkes A and Friedman E . (2001). Br. J. Cancer, 84, 478–481.

  • Giardiello FM, Brensinger JD, Tersmette AC, Goodman SN, Petersen GM, Booker SV, Cruz-Correa M and Offerhaus JA . (2000). Gastroenterology, 119, 1447–1453.

  • Goggins M, Schutte M, Lu J, Moskaluk CA, Weinstein CL, Petersen GM, Yeo CJ, Jackson CE, Lynch HT, Hruban RH and Kern SE . (1996). Cancer Res., 56, 5360–5364.

  • Goldstein AM, Fraser MC, Struewing JP, Hussussian CJ, Ranade K, Zametkin DP, Fontaine LS, Organic SM, Dracopoli NC, Clark WHJ and Tucker MA . (1995). N. Engl. J. Med., 333, 970–974.

  • Hahn SA, Greenhalf B, Ellis I, Sina-Frey M, Rieder H, Korte B, Gerdes B, Kress R, Ziegler A, Raeburn JA, Campra D, Grutzmann R, Rehder H, Rothmund M, Schmiegel W, Neoptolemos JP and Bartsch DK . (2003). J. Natl. Cancer Inst., 95, 214–221.

  • Haraldsson K, Loman N, Zhang QX, Johannsson O, Olsson H and Borg A . (1998). Cancer Res., 58, 1367–1371.

  • Howlett NG, Taniguchi T, Olson S, Cox B, Waisfisz Q, De Die-Smulders C, Persky N, Grompe M, Joenje H, Pals G, Ikeda H, Fox EA and D’Andrea AD . (2002). Science, 297, 606–609.

  • Klein AP, Hruban RH, Brune KA, Petersen GM and Goggins M . (2001). Cancer J., 7, 266–273.

  • Krainer M, Silva-Arrieta S, FitzGerald MG, Shimada A, Ishioka C, Kanamaru R, MacDonald DJ, Unsal H, Finkelstein DM, Bowcock A, Isselbacher KJ and Haber DA . (1997). N. Engl. J. Med., 336, 1416–1421.

  • Lim W, Olschwang S, Keller JJ, Westerman AM, Menko FH, Boardman LA, Scott RJ, Trimbath J, Giardiello FM, Gruber SB, Gille JJ, Offerhaus GJ, de Rooij FW, Wilson JH, Spigelman AD, Phillips RK and Houlston RS . (2004). Gastroenterology, 126, 1788–1794.

  • Lowenfels AB, Maisonneuve P, Cavallini G, Ammann RW, Lankisch PG, Andersen JR, Dimagno EP, Andren-Sandberg A and Domellof L . (1993). N. Engl. J. Med., 328, 1433–1437.

  • Lowenfels AB, Maisonneuve P, DiMagno EP, Elitsur Y, Gates Jr LK, Perrault J and Whitcomb DC . (1997). J. Natl. Cancer Inst., 89, 442–446.

  • Lynch HT, Brand RE, Lynch JF, Fusaro RM, Smyrk TC, Goggins M and Kern SE . (2000). Gastroenterology, 119, 1756–1760.

  • Matsubayashi H, Fukushima N, Sato N, Brune K, Canto M, Yeo CJ, Hruban RH, Kern SE and Goggins M . (2003). Cancer Biol. Ther., 2, 652–655.

  • Mazoyer S, Dunning AM, Serova O, Dearden J, Puget N, Healey CS, Gayther SA, Mangion J, Stratton MR, Lynch HT, Goldgar DE, Ponder BA and Lenoir GM . (1996). Nat. Genet., 14, 253–254.

  • Morimatsu M, Donoho G and Hasty P . (1998). Cancer Res., 58, 3441–3447.

  • Murphy KM, Brune KA, Griffin C, Sollenberger JE, Petersen GM, Bansal R, Hruban RH and Kern SE . (2002). Cancer Res., 62, 3789–3793.

  • Niederhuber JE, Brennan MF and Menck HR . (1995). Cancer, 76, 1671–1677.

  • Ozcelik H, Schmocker B, Di Nicola N, Shi XH, Langer B, Moore M, Taylor BR, Narod SA, Darlington G, Andrulis IL, Gallinger S and Redston M . (1997). Nat. Genet., 16, 17–18.

  • Petersen GM and Hruban RH . (2003). J. Natl. Cancer Inst., 95, 180–181.

  • Rogers C, van der Heijden MS, Brune K, Yeo CJ, Hruban RH, Kern SE and Goggins M . (2004). Cancer Biol. Ther., 3, 16709.

  • van der Heijden MS, Yeo CJ, Hruban RH and Kern SE . (2003). Cancer Res., 63, 2585–2588.

  • Vasen HF, Gruis NA, Frants RR, van Der Velden PA, Hille ET and Bergman W . (2000). Int. J. Cancer, 87, 809–811.

  • Wang X, Andreassen PR and D’Andrea AD . (2004). Mol. Cell. Biol., 24, 5850–5862.

  • Yamamoto H, Itoh F, Nakamura H, Fukushima H, Sasaki S, Perucho M and Imai K . (2001). Cancer Res., 61, 3139–3144.

  • Yeo CJ, Sohn TA, Cameron JL, Hruban RH, Lillemoe KD and Pitt HA . (1998). Ann. Surg., 227, 821–831.

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Michael Goggins.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Martin, S., Matsubayashi, H., Rogers, C. et al. Increased prevalence of the BRCA2 polymorphic stop codon K3326X among individuals with familial pancreatic cancer. Oncogene 24, 3652–3656 (2005). https://doi.org/10.1038/sj.onc.1208411

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1208411

Keywords

This article is cited by

Search

Quick links